Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements

Fineline Cube Jul 13, 2026
Company Deals

Teva Secures Global Rights to Polpharma Biologics’ Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio

Fineline Cube Jul 13, 2026
Company Deals

Drug Farm Closes First Tranche of $55 Million Series D Financing to Advance First-in-Class Pipeline Across Multiple Therapeutic Areas

Fineline Cube Jul 13, 2026
Company Deals

Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development

Fineline Cube Jul 13, 2026
Company Deals

Triastek Secures Strategic Financing to Advance 3D-Printed Oral Peptide Pipeline and Build Shanghai International R&D Center

Fineline Cube Jul 13, 2026
Policy / Regulatory

China’s National Health Commission Launches Comprehensive Continuous Medication Management Framework to Enhance Patient Safety and Healthcare Quality

Fineline Cube Jul 13, 2026
Company Drug

EMA CHMP Recommends Revocation of TAVNEOS Marketing Authorization Following Data Integrity Concerns in ADVOCATE Trial

Fineline Cube Jul 13, 2026
Company Drug

Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors

Fineline Cube Jul 13, 2026
Company Drug

Jiangsu Aidea’s HIV-1 Drug ACC017 Accepted for NMPA Review in China

Fineline Cube Oct 25, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...

Company Drug

Shandong Luoxin’s LX-039 Demonstrates Promise in Phase I Oncology Study at ESMO

Fineline Cube Oct 24, 2023

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a China-based pharmaceutical innovator, has published...

Company Drug

Kintor’s Proxalutamide Shows Promise in Metastatic Breast Cancer Study at ESMO

Fineline Cube Oct 24, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published the latest data from a Phase Ic...

Company Drug

Walvax Biotechnology Secures BPOM Approval for Weuphoria Pneumococcal Vaccine

Fineline Cube Oct 24, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received market approval...

Policy / Regulatory

NMPA Implements New Measures for Drug Manufacturing Outsourcing by MAHs

Fineline Cube Oct 24, 2023

The National Medical Products Administration (NMPA) has issued a notice detailing new supervision and management...

Company Drug

Ascentage Pharma’s Pelcitoclax Shows Promise in ESMO Study for NSCLC

Fineline Cube Oct 24, 2023

Suzhou-based pharmaceutical company Ascentage Pharma (HKG: 6855) has published the latest results from a Phase...

Company Drug

Changchun BCHT Biotechnology Invests in Influenza Vaccine Production Expansion

Fineline Cube Oct 24, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced plans to invest RMB 805...

Company Drug

Yiling Pharmaceutical Gains NMPA Approval for XY0206 in AML Trial

Fineline Cube Oct 24, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...

Company Drug

Chengdu Kanghong Receives FDA Nod for Clinical Trial of Novel Depression Therapy KH607

Fineline Cube Oct 24, 2023

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced that it has received...

Company Medical Device

Blue Sail Medical Enrolls First Patient in Study for Rapamycin-Coated Balloon Catheter

Fineline Cube Oct 24, 2023

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced a significant milestone with the...

Company Drug

Transcenta Holdings Unveils Updated Osemitamab Data in Advanced Gastric Cancer at ESMO

Fineline Cube Oct 24, 2023

China-based biotech Transcenta Holdings Ltd (HKG: 6628) has presented updated efficacy data from the expansion...

Company Drug

Vcanbio Receives NMPA Approval for Clinical Study of VUM02 in SR-aGvHD Treatment

Fineline Cube Oct 24, 2023

China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that...

Company Deals

Roche Agrees to Acquire Telavant for $7.1 Billion to Boost IBD Treatment Portfolio

Fineline Cube Oct 24, 2023

Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) announced this week an agreement to purchase Telavant Holdings,...

Company Deals

J&J MedTech Partners with CED Medical for Neurointerventional Solutions

Fineline Cube Oct 24, 2023

Johnson & Johnson MedTech’s (J&J, NYSE: JNJ) Shanghai-based subsidiary, Johnson Johnson Medical Equipment Co., Ltd,...

Company Drug

Alphamab Oncology Presents Promising Data for KN046 and KN026 at ESMO 2023

Fineline Cube Oct 24, 2023

China-based Alphamab Oncology (HKG: 9966) has released data snapshots from clinical studies for two of...

Company Drug

Janssen’s TAR-200 Shows High Complete Response Rate in Bladder Cancer Study

Fineline Cube Oct 23, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has published data from a Phase IIb...

Company Drug

Novartis’ Kisqali Plus Endocrine Therapy Shows Improved Survival in Early Breast Cancer Study

Fineline Cube Oct 23, 2023

Switzerland-based pharmaceutical company Novartis (NYSE: NVS) has announced additional results from an ongoing Phase III...

Company

Boehringer Ingelheim Appoints Mohammed Tawil as New CEO for Greater China Region

Fineline Cube Oct 23, 2023

Germany’s Boehringer Ingelheim (BI) has announced a leadership transition within its Greater China region, which...

Company Drug

Pfizer’s Penbraya Receives FDA Approval for Meningococcal Immunization

Fineline Cube Oct 23, 2023

Pfizer Inc. (NYSE: PFE) announced last week that it has successfully registered its pentavalent meningococcal...

Policy / Regulatory

National VBP Tender Program Invites Drugs Approved Before October 30 for Round 9

Fineline Cube Oct 23, 2023

The National Allied Procurement Office has released a notification regarding Round 9 of the national...

Posts pagination

1 … 483 484 485 … 694

Recent updates

  • Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements
  • Teva Secures Global Rights to Polpharma Biologics’ Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio
  • EMA CHMP Recommends Revocation of TAVNEOS Marketing Authorization Following Data Integrity Concerns in ADVOCATE Trial
  • China’s National Health Commission Launches Comprehensive Continuous Medication Management Framework to Enhance Patient Safety and Healthcare Quality
  • Drug Farm Closes First Tranche of $55 Million Series D Financing to Advance First-in-Class Pipeline Across Multiple Therapeutic Areas
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements

Company Deals

Teva Secures Global Rights to Polpharma Biologics’ Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio

Company Drug

EMA CHMP Recommends Revocation of TAVNEOS Marketing Authorization Following Data Integrity Concerns in ADVOCATE Trial

Policy / Regulatory

China’s National Health Commission Launches Comprehensive Continuous Medication Management Framework to Enhance Patient Safety and Healthcare Quality

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.